Net Income

The burger chain posted robust revenue and a massive jump in annual net income, outperforming rivals and detailing plans for major global expansion.

With promising data for its oral STAT6 degrader and a cash runway into 2029, Kymera Therapeutics is poised to disrupt the injectable-dominated market.

Kairos Pharma aims to reshape lung cancer treatment by acquiring two AI-designed drugs, targeting a key resistance mechanism in a multi-billion dollar market.

After a massive divestiture, Vistance Networks reports soaring growth, zero debt, and plans a huge special cash distribution to its shareholders.

Facing slow auto OEM cycles, Arbe Robotics names a new CEO and targets defense, robotaxis, and China to accelerate revenue from its high-res radar tech.

With a key FDA decision looming and pivotal data on a second therapy imminent, Viridian is poised to reshape the multi-billion dollar Thyroid Eye Disease market.

As colorectal cancer rates rise in younger adults, advocates demand provinces lower the screening age. But will policymakers act on the growing evidence?

After a strong 2025, Viatris unveils a plan for $650M in savings, a 10% workforce cut, and a focus on six new drugs to fuel future innovation.

The energy giant unveils a massive capital plan to boost regulated assets, even as a $471M write-down on renewables reveals significant grid challenges.

With record SUBLOCADE revenue and a new U.S. home, Indivior launches a $400M buyback, signaling a new era in its fight against the opioid crisis.

With soaring sales for its rare obesity drug IMCIVREE, Rhythm Pharmaceuticals faces a critical March FDA decision that could unlock a massive new market.

New analyses of Upstream Bio's verekitug aim to prove its true effectiveness for nasal polyps, setting the stage for a competitive showdown.

Semiconductor firm Aeluma will meet investors at the ROTH conference, betting its unique, scalable chip technology is the key to powering the future of AI and AR/VR.

A new collaboration is betting on tiny natural particles to deliver a gene-editing cure for a devastating neurological disorder, bypassing a key medical hurdle.

Eos Energy reports record revenue and a fortified balance sheet, resolving 'going concern' doubts, but sets 2026 guidance below analyst expectations.

After strong 2025 results, the infrastructure supplier is building a new US factory to capitalize on grid modernization, offsetting softer lumber markets.

With $62B in 2025 funding and a 17% surge, Origence is arming credit unions with AI and embedded finance to compete in a rapidly changing market.

Perrigo takes a massive $1.3B impairment charge and plans a 7% workforce reduction as it pivots to a 'CORE' business amid a challenging outlook.

The hydration giant posts a 29% revenue jump to $6.7B in its first year, signaling a strong start, but focuses on fixing customer service snags.

Titan International beat expectations in Q4, driven by a 21% surge in its construction division, and now eyes a strong 2026 as OEM destocking ends.